原发性卵巢肉瘤与上皮性卵巢癌的发病率及生存结局比较:韩国国家癌症登记研究
基于韩国中央癌症登记1999—2017年数据,比较原发性卵巢肉瘤(n=1361)与上皮性卵巢癌(n=30366)的年龄标准化发病率和相对生存率。卵巢肉瘤ASR为0.22/10万女性,上皮性卵巢癌为4.75/10万女性,ASR比值为21.94,研究期间ASR无显著变化。两组5年总生存率分别为64.0%与61.5%,差异无统计学意义(p=0.6030)。
要点
- 原发性卵巢肉瘤ASR为0.22/10万女性,上皮性卵巢癌为4.75/10万女性,ASR比值21.94。
- 研究期间两者ASR均无显著变化。
- 纯肉瘤中纤维肉瘤亚型总生存最佳,5年总生存85.0%(p<0.0001)。
核心结论
- 原发性卵巢肉瘤发病率很低,过去20年ASR为0.22/10万。
- 原发性卵巢肉瘤与上皮性卵巢癌的生存率无显著差异。
研究设计与样本
- 基于韩国中央癌症登记1999—2017年数据的回顾性队列研究。
- 纳入原发性卵巢肉瘤患者1361例和上皮性卵巢癌患者30366例。
- 计算并比较年龄标准化发病率(ASR)和相对生存率。
主要发现
- 上皮性卵巢癌ASR为4.75/10万女性,原发性卵巢肉瘤ASR为0.22/10万女性。
- ASR比值为21.94,研究期间ASR无显著变化。
- 原发性卵巢肉瘤生存曲线优于上皮性卵巢癌,但差异无统计学意义(5年总生存64.0% vs. 61.5%;p=0.6030)。
- 纯肉瘤中纤维肉瘤亚型总生存最佳,脂肪肉瘤和间质细胞肉瘤次之(5年总生存85.0%、76.7%、72.7%;p<0.0001)。
临床怎么用
- 临床中需注意原发性卵巢肉瘤发病率极低,ASR仅0.22/10万女性。
- 原发性卵巢肉瘤与上皮性卵巢癌的5年总生存率相近(64.0% vs. 61.5%)。
- 纯肉瘤中纤维肉瘤亚型预后相对较好,5年总生存达85.0%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the incidence and survival outcomes of primary ovarian sarcoma compared to those of epithelial ovarian cancer. METHODS: Data on primary ovarian sarcoma patients (n = 1361) and epithelial ovarian cancer patients (n = 30,366) between 1999 and 2017 were obtained from the Korea Central Cancer Registry, and their respective age-standardized incidence rate (ASR) and relative survival rate were calculated and compared. RESULTS: Based on the ASR, the incidence of epithelial ovarian cancer was 4.75 per 100,000 women, while that of primary ovarian sarcoma was 0.22 per 100,000 women. The ASR ratio was 21.94 without significant change of ASR during the study period. Primary ovarian sarcoma had a better survival curve compared with epithelial ovarian cancer, though the difference was not statistically significant (5 yr overall survival 64.0% vs. 61.5%; p = 0.6030). In addition, among the pure sarcomas, the fibrosarcoma histologic subtype showed the best overall survival, and that of liposarcomas and stromal cell sarcoma were behind that (5 yr overall survival 85.0%, 76.7%, and 72.7%; p < 0.0001). CONCLUSIONS: The incidence of primary ovarian sarcoma is quite low, with an ASR of 0.22/100,000 during the last 20 years. There were no significant differences between survival rates of primary ovarian sarcoma and epithelial ovarian cancer.
引用
- Ha HI, Cho SH, Lim J, et al. Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry. Gynecol Oncol. 2021. PMID: 34602286. doi:10.1016/j.ygyno.2021.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。